GENMAB A/S

Genmab A/S

Biotechnology • Healthcare • Copenhagen, Denmark • GNMSF (PNK)

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

45 70 20 27 28 Carl Jacobsens Vej 30, Denmark

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Above 50-Day Moving Average - Time to Sell? - MarketBeat
MarketBeat • Dec 16
Why Genmab Stock Popped on Friday - The Motley Fool
The Motley Fool • Oct 3
Genmab stock falls after discontinuing acasunlimab development - Investing.com
Investing.com • Dec 29
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - Nasdaq
Nasdaq • Oct 3
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - Yahoo Finance
Yahoo Finance • Nov 19

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has GENMAB A/S had layoffs?
No layoff events have been recorded for GENMAB A/S in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does GENMAB A/S have?
GENMAB A/S has approximately 2,681 employees.
What industry is GENMAB A/S in?
GENMAB A/S operates in the Biotechnology industry, within the Healthcare sector.
Is GENMAB A/S a publicly traded company?
Yes, GENMAB A/S is publicly traded under the ticker symbol GNMSF on the PNK. The company has a market capitalization of approximately $20.53 billion.
Where is GENMAB A/S headquartered?
GENMAB A/S is headquartered in Copenhagen, Denmark at Carl Jacobsens Vej 30, Denmark.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.